Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



An Approval. Finally.

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Amylin Pharmaceuticals' (Nasdaq: AMLN  ) investors were able to breathe a sigh of relief on Friday, when the Food and Drug Administration approved the company's diabetes drug, Bydureon. Finally.

This wasn't one of those instant doubles on approval because most investors figured a thumbs-up was likely, but given the last attempt at approval, investors were right to be nervous and discount the value slightly. The stock is up 20% today. Surprisingly, Alkermes (Nasdaq: ALKS  ) is trading lower even though it'll get a nice royalty on the drug's sales. Eli Lilly (NYSE: LLY  ) , which also gets a royalty, is down as well, but Lilly isn't that dependent on the drug.

Bydureon is the once-weekly version of Byetta, which has to be taken twice daily.  Eliminating 13 shots from the patient's weekly routine should help sell the new medication, but Bydureon won't just be cannibalizing sales from Byetta. Novo Nordisk's (NYSE: NVO  ) Victoza, which needs to be injected just once a day, not only took sales from Byetta but expanded the market for the class of drugs. Amylin is hoping it can return the favor and continue the trend.

Bydureon is approved as a monotherapy, but only as a second-line indication. That means doctors aren't advised to use Bydureon on a newly diagnosed patient, but could prescribe it for use by itself if patients fail another drug. I don't think that's a major issue, because I doubt there are many doctors who wouldn't try metformin first. Bydureon is arguably a better drug, but "better" may not be necessary in newly diagnosed patients. If the diabetes is controlled -- for the time being -- by a cheap oral generic that's been approved since 1995, there's little reason to give anything stronger. Diabetes is a progressive disease, so Bydureon will get its chance at the patient eventually.

It's also approved for use in conjunction with other oral drugs, so theoretically Bydureon won't have to compete directly with the multi-billion-dollar drugs such as Merck's (NYSE: MRK  ) Januvia. In reality, the branded drugs probably will compete, since doctors won't want to burden patients with two large copays; Bydureon will probably be prescribed with generics most often.

With an approval in hand, investors will have to take another breath and hold it until first-quarter results are announced, where we'll get a look at how well Amylin can sell the improved version of the drug.

And while we are discussing upcoming earnings, grab a copy of the Fool's new report highlighting companies out there that investors need to watch during this earnings season. In the Fool's "Fourth-Quarter Earnings Report: 7 Stocks You'll Want to Watch," you'll find information on this quarter's possible big performers. It's completely free for our readers, so click here to access yours today.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1768953, ~/Articles/ArticleHandler.aspx, 10/28/2016 6:40:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
ALKS $51.72 Down -1.52 -2.85%
Alkermes CAPS Rating: ****
LLY $76.16 Down -0.60 -0.78%
Eli Lilly and Co. CAPS Rating: ***
MRK $61.29 Up +0.42 +0.69%
Merck and Co. CAPS Rating: ****
NVO $40.94 Up +0.70 +1.74%
Novo Nordisk CAPS Rating: *****